|
Advanced Clinical Integration and Accountable Care
|
|
JOHN MARREN, ESQ.
THOMAS BABBO, ESQ.
HOGAN MARRENT, LTD., CHICAG
FACULTY DISCLOURE: According to the CMA guidelines on faculty discloure of commerical support, we are required to announce the following: Mr. Marren and Mr. Babbo state they have no disclosures.
Myron Berdischewsky, M.D., planner of the clinical integration sessions, states he has no disclosures.
Objectives
At the end of the presentation, attendees will be able to: - discuss the implications of healthcare reform on the care delivery system.
-
describe current successful models of collaboration between private practice physicians and hospitals based on clinical integration across the care continuum
- articulate the legal requirements of the clinical integratin model, and how it relates to clinical quality,
- discuss what Providence California Region is doing to support physicians in continuing to deliver high quality care in the practice model of their choice.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
|
|
Prevention and Treatment of Vitamin D Deficiency: Endocrinology Perspective
|
|
YAROSLAV GOFNUNG, M.D.
DEPARTMENT OF MEDICINE, PSJMC
MODERATOR: Paola Tempesti, M.D.; Department of Medicine, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following:
Dr. Gofnung states he has no disclosures. Dr. Tempesti states she has stock in Bristol Myers Squibb.
OBJECTIVES
At the end of the presentation, attendees will be able to: - identify who is at risk for Vitamin D deficiency and recognize the signs and symptoms.
- conduct an appropriate work-up for Vitamin D status and interpret results.
- incorporate into practice the latest recommendations for prevention and treatment of Vitamin D deficiency.
- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of Vitamin D deficiency.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
|